Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid

Objectives: The objective of this study was to evaluate the efficacy and safety of the sequential use of bedaquiline (Bdq) and delamanid (Dlm) in patients with multidrug-resistant tuberculosis (MDR-TB) and limited treatment options. Methods: This study evaluated 74 MDR-TB patients treated between Ma...

Full description

Bibliographic Details
Main Authors:	Hoon Hee Lee, Kyung-Wook Jo, Jae-Joon Yim, Doosoo Jeon, Hyungseok Kang, Tae Sun Shim
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	International Journal of Infectious Diseases
Subjects:	Bedaquiline Delamanid Treatment outcome Tuberculosis MDR
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971220305439

Similar Items

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
by: Uzma Khan, et al.
Published: (2019-08-01)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
by: Giovanni Battista Migliori, et al.
Published: (2017-02-01)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
by: Andrey Maryandyshev, et al.
Published: (2017-10-01)

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
by: S. Koirala, et al.
Published: (2021-09-01)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
by: Hu MH, et al.
Published: (2016-12-01)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01)

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China
by: Wencong He, et al.
Published: (2021-09-01)

Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains
by: Battaglia, S., et al.
Published: (2021)

Classifying new anti-tuberculosis drugs: rationale and future perspectives
by: Simon Tiberi, et al.
Published: (2017-03-01)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
by: Jay Achar, et al.
Published: (2017-10-01)

Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty?
by: Aleksey G. Naumov, et al.
Published: (2018-11-01)

Tuberculose à bacilles résistants aux antibiotiques en France : épidémiologie et prise en charge
by: Guglielmetti, Lorenzo
Published: (2018)

Effekten och potentiella risker med bedaquiline, delamanid och pretomanid vid behandling av multiresistent tuberkulos
by: Jansson, Alexandra
Published: (2019)

New regimens and new medications in the treatment of tuberculosis: keeping step?
by: Ruzanov D.Y., et al.
Published: (2021-04-01)

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
by: L. Guglielmetti, et al.
Published: (2021-09-01)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017-01-01)

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis
by: Saeed Khoshnood, et al.
Published: (2021-10-01)

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis
by: Jennifer Furin, et al.
Published: (2016-03-01)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
by: Marie Jaspard, et al.
Published: (2017-10-01)

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
by: Villellas, C., et al.
Published: (2019)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
by: Shereen Katrak, et al.
Published: (2021-05-01)

Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects
by: V. N. Zimina, et al.
Published: (2021-03-01)

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01)

Six-Month Response to Delamanid Treatment in MDR TB Patients
by: Cathy Hewison, et al.
Published: (2017-10-01)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
by: Jian Du, et al.
Published: (2021-05-01)

Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis
by: H Nagabushan, et al.
Published: (2014-01-01)

Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients
by: Jingtao Gao, et al.
Published: (2020-11-01)

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
by: Myungsun Lee, et al.
Published: (2019-01-01)

Cardiac toxicity of fluoroquinolones and bedaquiline
by: G. N. Mozhokinа, et al.
Published: (2019-05-01)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
by: Jing-Tao Gao, et al.
Published: (2021-03-01)

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience
by: Alena Skrahina, et al.
Published: (2016-01-01)

Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
by: Lawrence Mbuagbaw, et al.
Published: (2019-05-01)

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis
by: Jinmeng Li, et al.
Published: (2021-09-01)

atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure
by: Aubry, A., et al.
Published: (2022)

Maleate salts of bedaquiline
by: Matthias Zeller, et al.
Published: (2021-04-01)

Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)

The efficacy and safety of bedaquiline in multi-drug resistant tuberculosis
by: Lu, Edgar
Published: (2018)

Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in Mycobacterium abscessus
by: Anandi Martin, et al.
Published: (2020-01-01)

Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study
by: Nazir A. Ismail, et al.
Published: (2018-02-01)